{"created":"2023-05-15T14:47:48.703340+00:00","id":65551,"links":{},"metadata":{"_buckets":{"deposit":"5e51bc14-6c3c-4492-a93f-f4bd78e97729"},"_deposit":{"created_by":1,"id":"65551","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"65551"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00065551","sets":["10:29"]},"author_link":["645610","645612","645607","645613","645611","645609","645608"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2014-12-13","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"放医研では今まで520例以上の重粒子線による肝癌治療を行っており、良好な治療成績を得ているが、進行癌の５年生存率は依然50%以下であり、有効な治療対策が強く望まれている。本研究では、超高速セルソーターを用いて肝癌細胞株Huh7、HepG2より癌幹細胞を同定・分離し、炭素線単独或はSorafenibとの併用によるこれら癌幹細胞に対する生存、DNA損傷、腫瘍抑制効果の違いをX線照射のものと比較検討した。Huh7、HepG2細胞においてCD133+/CD90+、CD44+/ESA+細胞集団はCD133-/CD90-、CD44-/ESA-細胞集団に比べ有意にコロニー形成数とspheroid形成数が多いことが確認され、X線、炭素線照射に対しともに抵抗性を示すが、炭素線単独或はSorafenibとの併用はX線照射のものに比べ、コロニーやspheroid形成能を顕著に抑制し、処置24h後のγH2AX foci残存が有意に多いことが認められた。また、炭素線はX線照射に比べより強い腫瘍抑制効果を示し、Sorafenibとの併用はより有効に肝癌幹細胞マーカーの発現を抑制することが認められた。以上より、肝癌細胞において、Sorafenibとの併用は炭素線単独照射に比べ比較的低い線量でもより強く肝癌幹細胞を殺傷することが示唆された。","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第26回日本放射線腫瘍学会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"崔, 星"}],"nameIdentifiers":[{"nameIdentifier":"645607","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"若井俊文"}],"nameIdentifiers":[{"nameIdentifier":"645608","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"上條, 岳彦"}],"nameIdentifiers":[{"nameIdentifier":"645609","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"白井, 敏之"}],"nameIdentifiers":[{"nameIdentifier":"645610","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"崔 星","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"645611","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"上條 岳彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"645612","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"白井 敏之","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"645613","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"肝癌幹細胞に対する重粒子単独或はSorafenibとの併用による殺傷効果","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"肝癌幹細胞に対する重粒子単独或はSorafenibとの併用による殺傷効果"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-12-15"},"publish_date":"2014-12-15","publish_status":"0","recid":"65551","relation_version_is_last":true,"title":["肝癌幹細胞に対する重粒子単独或はSorafenibとの併用による殺傷効果"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:58:51.084025+00:00"}